Walleye Capital
MPLT

Walleye Capital’s MapLight Therapeutics MPLT Stock Holding History

Walleye Capital’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,572
Closed -$235K – 5286
2026
Q1 		$235K Sell
11,572
-114
-1% -$2.04K ﹤0.01% 3229
2025
Q4 		$205K Buy
+11,686
New +$196K ﹤0.01% 3535

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's MPLT Position: Q2 2026 in Review

Walleye Capital sold out of MapLight Therapeutics (MPLT) in Q2 2026, closing a stake of 11,572 shares — an estimated $235K sold.

Walleye Capital first reported a position in MPLT in Q4 2025 and held it in 2 quarters. The position peaked at $235K in Q1 2026. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Walleye Capital reported no remaining MapLight Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 11,572 MapLight Therapeutics shares in Q2 2026, an estimated $235K.
  • Walleye Capital first reported a position in MapLight Therapeutics in Q4 2025 and held it in 2 quarters.
  • Walleye Capital's MapLight Therapeutics position peaked at $235K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.